世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

世界のVREおよびMRSA抗生物質市場プロフェッショナル調査報告書2021年版

世界のVREおよびMRSA抗生物質市場プロフェッショナル調査報告書2021年版


Global VRE and MRSA Antibiotic Market Professional Survey Report 2021

VREおよびMRSA抗生物質の世界市場は、2020年に37億米ドルと評価されましたが、2021年から2027年の間に4.00%のCAGRで成長し、2027年末には51億米ドルに達する見込みです。 本レポートでは、世界レベル、地域レベ... もっと見る

　

　

出版社 出版年月 電子版価格 納期 言語
QYResearch
QYリサーチ 		2021年11月21日 US$3,500
シングルユーザライセンス
ライセンス・価格情報
注文方法はこちら 		5-7営業日 英語

※当ページの内容はウェブ更新時の情報です。
最新版の価格やページ数などの情報についてはお問合せください。
日本語のページは自動翻訳を利用し作成しています。
実際のレポートは英文のみでご納品いたします。


　

サマリー

VREおよびMRSA抗生物質の世界市場は、2020年に37億米ドルと評価されましたが、2021年から2027年の間に4.00%のCAGRで成長し、2027年末には51億米ドルに達する見込みです。
本レポートでは、世界レベル、地域レベル、企業レベルでのVREおよびMRSA抗生物質の数量と価値に焦点を当てています。世界的な観点から、本レポートは過去のデータと将来の展望を分析することで、VREとMRSAの抗生物質の全体的な市場規模を表しています。
地域別では、北米、欧州、中国、韓国などにおけるVREおよびMRSA用抗生物質の販売を分類しています。
対象メーカーについては、VRE・MRSA抗生物質の製造拠点、売上高、工場出荷時価格、売上高、各企業の市場シェアなどを分析しています。
会社別
ファイザー
リリー
サノフィ・アベンティス
メルク
フレゼニウス・カビ
ゼリア新薬(ノボ・ホールディングス)
浙江省医学
浙江久順製薬
華北製薬
韓国聯合製薬(株)
タイプ別セグメント
バンコマイシン
テイコプラニン
リネゾリド
ダプトマイシン
その他
用途別セグメント
病院
クリニック
その他
地域別
北アメリカ
ヨーロッパ
日本
中国
ラテンアメリカ
インド

ページTOPに戻る


目次


1 INDUSTRY OVERVIEW OF VRE AND MRSA ANTIBIOTIC 1
1.1 Definition of VRE and MRSA Antibiotic 1
1.2 VRE and MRSA Antibiotic Segment by Type 2
1.2.1 Global VRE and MRSA Antibiotic Sales Growth Rate Comparison by Type (2021-2027) 2
1.2.2 Vancomycin 3
1.2.3 Teicoplanin 4
1.2.4 Linezolid 5
1.2.5 Daptomycin 6
1.2.6 Others 7
1.3 VRE and MRSA Antibiotic Segment by Application 7
1.3.1 Global VRE and MRSA Antibiotic Sales Comparison by Application (2021-2027) 7
1.3.2 Hospitals 8
1.3.3 Clinics 9
1.4 VRE and MRSA Antibiotic Overall Market: 2016 VS 2021 VS 2027 9
1.4.1 Global VRE and MRSA Antibiotic Revenue (2016-2027) 10
1.4.2 Global VRE and MRSA Antibiotic Sales (2016-2027) 12
1.4.3 North America VRE and MRSA Antibiotic Status and Prospect (2016-2027) 13
1.4.4 Europe VRE and MRSA Antibiotic Status and Prospect (2016-2027) 14
1.4.5 China VRE and MRSA Antibiotic Status and Prospect (2016-2027) 15
1.4.6 Japan VRE and MRSA Antibiotic Status and Prospect (2016-2027) 16
1.4.7 South Korea VRE and MRSA Antibiotic Status and Prospect (2016-2027) 17
1.4.8 Latin America VRE and MRSA Antibiotic Status and Prospect (2016-2027) 18
1.5 VRE and MRSA Antibiotic Research Status 18
2 MANUFACTURING COST STRUCTURE ANALYSIS 21
2.1 Raw Material and Suppliers 21
2.2 Manufacturing Cost Structure Analysis of VRE and MRSA Antibiotic 22
2.3 Manufacturing Process Analysis of VRE and MRSA Antibiotic 23
2.4 Industry Chain Structure of VRE and MRSA Antibiotic 24
3 DEVELOPMENT AND MANUFACTURING PLANTS ANALYSIS OF VRE AND MRSA ANTIBIOTIC 25
3.1 Top Manufacturers Headquarters, Rank by VRE and MRSA Antibiotic Sales 25
3.2 Global VRE and MRSA Antibiotic Manufacturing Plants Distribution and Establish Date 25
3.3 Major Manufacturers VRE and MRSA Antibiotic Product Offered 26
3.4 Recent Development and Expansion Plans 26
4 KEY FIGURES OF MAJOR MANUFACTURERS 28
4.1 Global Top Manufacturers VRE and MRSA Antibiotic Sales Analysis 28
4.2 Global Top Manufacturers VRE and MRSA Antibiotic Revenue Analysis 30
4.3 Global Top Manufacturers VRE and MRSA Antibiotic Price Analysis 32
4.4 Market Concentration Degree 32
5 VRE AND MRSA ANTIBIOTIC REGIONAL MARKET ANALYSIS 35
5.1 VRE and MRSA Antibiotic Sales by Regions (2016-2021) 35
5.1.1 Global VRE and MRSA Antibiotic Sales by Regions (2016-2021) 35
5.1.2 Global VRE and MRSA Antibiotic Revenue by Regions 36
5.2 VRE and MRSA Antibiotic Sales by Regions (2022-2027) 37
5.2.1 Global VRE and MRSA Antibiotic Sales by Regions (2022-2027) 37
5.2.2 Global VRE and MRSA Antibiotic Revenue by Regions 38
5.3 North America VRE and MRSA Antibiotic Market Analysis 39
5.3.1 North America VRE and MRSA Antibiotic Sales 39
5.3.2 Key Players in North America 39
5.4 Europe VRE and MRSA Antibiotic Market Analysis 40
5.4.1 Europe VRE and MRSA Antibiotic Sales 40
5.4.2 Key Players in Europe 40
5.5 China VRE and MRSA Antibiotic Market Analysis 41
5.5.1 China VRE and MRSA Antibiotic Sales 41
5.5.2 Key Players in China 41
5.6 Japan VRE and MRSA Antibiotic Market Analysis 42
5.6.1 Japan VRE and MRSA Antibiotic Sales 42
5.6.2 Key Players in Japan 42
5.7 South Korea VRE and MRSA Antibiotic Market Analysis 43
5.7.1 South Korea VRE and MRSA Antibiotic Sales 43
5.7.2 Key Players in South Korea 43
5.8 Latin America VRE and MRSA Antibiotic Market Analysis 44
5.8.1 Latin America VRE and MRSA Antibiotic Sales 44
5.8.2 Key Players in Latin America 44
6 VRE AND MRSA ANTIBIOTIC SEGMENT MARKET ANALYSIS (BY TYPE) 45
6.1 Global VRE and MRSA Antibiotic Market Size by Type (2016-2021) 45
6.1.1 Global VRE and MRSA Antibiotic Sales by Type (2016-2021) 45
6.1.2 Global VRE and MRSA Antibiotic Revenue by Type (2016-2021) 45
6.2 Global VRE and MRSA Antibiotic Market Size by Type (2022-2027) 46
6.2.1 Global VRE and MRSA Antibiotic Sales by Type (2022-2027) 46
6.2.2 Global VRE and MRSA Antibiotic Revenue by Type (2022-2027) 47
6.3 VRE and MRSA Antibiotic Price by Type 47
7 VRE AND MRSA ANTIBIOTIC SEGMENT MARKET ANALYSIS (BY APPLICATION) 49
7.1 Global VRE and MRSA Antibiotic Sales Market Share by Application (2016-2021) 49
7.2 Global VRE and MRSA Antibiotic Sales Market Share by Application (2022-2027) 49
8 KEY COMPANIES PROFILED 51
8.1 Pfizer 51
8.1.1 Pfizer Corporation Information 51
8.1.2 Pfizer Description and Business Overview 51
8.1.3 Pfizer VRE and MRSA Antibiotic Sales, Revenue and Gross Margin (2018-2021) 52
8.1.4 Pfizer VRE and MRSA Antibiotic Product Portfolio 52
8.1.5 Pfizer Recent Developments/Updates 54
8.2 Lilly 54
8.2.1 Lilly Corporation Information 54
8.2.2 Lilly Description and Business Overview 55
8.2.3 Lilly VRE and MRSA Antibiotic Sales, Revenue and Gross Margin (2018-2021) 55
8.2.4 Lilly VRE and MRSA Antibiotic Product Portfolio 56
8.2.5 Lilly Recent Developments/Updates 57
8.3 Sanofi Aventis 57
8.3.1 Sanofi Aventis Corporation Information 57
8.3.2 Sanofi Aventis Description and Business Overview 57
8.3.3 Sanofi Aventis VRE and MRSA Antibiotic Sales, Revenue and Gross Margin (2018-2021) 58
8.3.4 Sanofi Aventis VRE and MRSA Antibiotic Product Portfolio 58
8.3.5 Sanofi Aventis Recent Developments/Updates 59
8.4 Merck 60
8.4.1 Merck Corporation Information 60
8.4.2 Merck Description and Business Overview 60
8.4.3 Merck VRE and MRSA Antibiotic Sales, Revenue and Gross Margin (2018-2021) 61
8.4.4 Merck VRE and MRSA Antibiotic Product Portfolio 61
8.4.5 Merck Recent Developments/Updates 62
8.5 Fresenius Kabi 62
8.5.1 Fresenius Kabi Corporation Information 62
8.5.2 Fresenius Kabi Description and Business Overview 62
8.5.3 Fresenius Kabi VRE and MRSA Antibiotic Sales, Revenue and Gross Margin (2018-2021) 63
8.5.4 Fresenius Kabi VRE and MRSA Antibiotic Product Portfolio 63
8.5.5 Fresenius Kabi Recent Developments/Updates 64
8.6 Xellia Pharmaceuticals (Novo Holdings) 65
8.6.1 Xellia Pharmaceuticals (Novo Holdings) Corporation Information 65
8.6.2 Xellia Pharmaceuticals (Novo Holdings) Description and Business Overview 65
8.6.3 Xellia Pharmaceuticals (Novo Holdings) VRE and MRSA Antibiotic Sales, Revenue and Gross Margin (2018-2021) 66
8.6.4 Xellia Pharmaceuticals (Novo Holdings) VRE and MRSA Antibiotic Product Portfolio 66
8.6.5 Xellia Pharmaceuticals (Novo Holdings) Recent Developments/Updates 67
8.7 Zhejiang Medicine 68
8.7.1 Zhejiang Medicine Corporation Information 68
8.7.2 Zhejiang Medicine Description and Business Overview 68
8.7.3 Zhejiang Medicine VRE and MRSA Antibiotic Sales, Revenue and Gross Margin (2018-2021) 69
8.7.4 Zhejiang Medicine VRE and MRSA Antibiotic Product Portfolio 70
8.8 Zhejiang Hisun Pharmaceutical 70
8.8.1 Zhejiang Hisun Pharmaceutical Corporation Information 70
8.8.2 Zhejiang Hisun Pharmaceutical Description and Business Overview 71
8.8.3 Zhejiang Hisun Pharmaceutical VRE and MRSA Antibiotic Sales, Revenue and Gross Margin (2018-2021) 71
8.8.4 Zhejiang Hisun Pharmaceutical VRE and MRSA Antibiotic Product Portfolio 72
8.8.5 Zhejiang Hisun Pharmaceutical Recent Developments/Updates 72
8.9 North China Pharmaceutical 72
8.9.1 North China Pharmaceutical Corporation Information 72
8.9.2 North China Pharmaceutical Description and Business Overview 73
8.9.3 North China Pharmaceutical VRE and MRSA Antibiotic Sales, Revenue and Gross Margin (2018-2021) 73
8.9.4 North China Pharmaceutical VRE and MRSA Antibiotic Product Portfolio 74
8.10 Korea United Pharm 75
8.10.1 Korea United Pharm Corporation Information 75
8.10.2 Korea United Pharm Description and Business Overview 75
8.10.3 Korea United Pharm VRE and MRSA Antibiotic Sales, Revenue and Gross Margin (2018-2021) 76
8.10.4 Korea United Pharm VRE and MRSA Antibiotic Product Portfolio 76
9 MARKETING CHANNEL, DISTRIBUTORS AND CUSTOMERS 77
9.1 VRE and MRSA Antibiotic Marketing Channel 77
9.1.1 Direct Channels 77
9.1.2 Indirect Channels 77
9.2 VRE and MRSA Antibiotic Distributors List 78
9.3 VRE and MRSA Antibiotic Customers 80
10 VRE AND MRSA ANTIBIOTIC MARKET DYNAMICS 81
10.1 VRE and MRSA Antibiotic Industry Trends 81
10.2 VRE and MRSA Antibiotic Growth Drivers 82
10.3 VRE and MRSA Antibiotic Market Challenges and Restraints 83
11 CONCLUSION 84
12 APPENDIX 85
12.1 Methodology/Research Approach 85
12.1.1 Research Programs/Design 85
12.1.2 Market Size Estimation 86
12.1.3 Market Breakdown and Data Triangulation 87
12.2 Data Source 88
12.2.1 Secondary Sources 88
12.2.2 Primary Sources 89
12.3 Author List 91
12.4 Disclaimer 91

　

ページTOPに戻る


　

Summary

The global VRE and MRSA Antibiotic market was valued at US$ 3.7 billion in 2020 and will reach US$ 5.1 billion by the end of 2027, growing at a CAGR of 4.00% during 2021-2027.
This report focuses on VRE and MRSA Antibiotic volume and value at the global level, regional level and company level. From a global perspective, this report represents overall VRE and MRSA Antibiotic market size by analyzing historical data and future prospect.
Regionally, this report categorizes the sales of VRE and MRSA Antibiotic in North America, Europe, China, South Korea, etc.
For the manufacturers covered, this report analyzes the VRE and MRSA Antibiotic manufacturing sites, sales, ex-factory price, revenue, and market share for each company.
By Company
Pfizer
Lilly
Sanofi Aventis
Merck
Fresenius Kabi
Xellia Pharmaceuticals (Novo Holdings)
Zhejiang Medicine
Zhejiang Hisun Pharmaceutical
North China Pharmaceutical
Korea United Pharm
Segment by Type
Vancomycin
Teicoplanin
Linezolid
Daptomycin
Others
Segment by Application
Hospitals
Clinics
Others
By Region
North America
Europe
Japan
China
Latin America
India



ページTOPに戻る


Table of Contents


1 INDUSTRY OVERVIEW OF VRE AND MRSA ANTIBIOTIC 1
1.1 Definition of VRE and MRSA Antibiotic 1
1.2 VRE and MRSA Antibiotic Segment by Type 2
1.2.1 Global VRE and MRSA Antibiotic Sales Growth Rate Comparison by Type (2021-2027) 2
1.2.2 Vancomycin 3
1.2.3 Teicoplanin 4
1.2.4 Linezolid 5
1.2.5 Daptomycin 6
1.2.6 Others 7
1.3 VRE and MRSA Antibiotic Segment by Application 7
1.3.1 Global VRE and MRSA Antibiotic Sales Comparison by Application (2021-2027) 7
1.3.2 Hospitals 8
1.3.3 Clinics 9
1.4 VRE and MRSA Antibiotic Overall Market: 2016 VS 2021 VS 2027 9
1.4.1 Global VRE and MRSA Antibiotic Revenue (2016-2027) 10
1.4.2 Global VRE and MRSA Antibiotic Sales (2016-2027) 12
1.4.3 North America VRE and MRSA Antibiotic Status and Prospect (2016-2027) 13
1.4.4 Europe VRE and MRSA Antibiotic Status and Prospect (2016-2027) 14
1.4.5 China VRE and MRSA Antibiotic Status and Prospect (2016-2027) 15
1.4.6 Japan VRE and MRSA Antibiotic Status and Prospect (2016-2027) 16
1.4.7 South Korea VRE and MRSA Antibiotic Status and Prospect (2016-2027) 17
1.4.8 Latin America VRE and MRSA Antibiotic Status and Prospect (2016-2027) 18
1.5 VRE and MRSA Antibiotic Research Status 18
2 MANUFACTURING COST STRUCTURE ANALYSIS 21
2.1 Raw Material and Suppliers 21
2.2 Manufacturing Cost Structure Analysis of VRE and MRSA Antibiotic 22
2.3 Manufacturing Process Analysis of VRE and MRSA Antibiotic 23
2.4 Industry Chain Structure of VRE and MRSA Antibiotic 24
3 DEVELOPMENT AND MANUFACTURING PLANTS ANALYSIS OF VRE AND MRSA ANTIBIOTIC 25
3.1 Top Manufacturers Headquarters, Rank by VRE and MRSA Antibiotic Sales 25
3.2 Global VRE and MRSA Antibiotic Manufacturing Plants Distribution and Establish Date 25
3.3 Major Manufacturers VRE and MRSA Antibiotic Product Offered 26
3.4 Recent Development and Expansion Plans 26
4 KEY FIGURES OF MAJOR MANUFACTURERS 28
4.1 Global Top Manufacturers VRE and MRSA Antibiotic Sales Analysis 28
4.2 Global Top Manufacturers VRE and MRSA Antibiotic Revenue Analysis 30
4.3 Global Top Manufacturers VRE and MRSA Antibiotic Price Analysis 32
4.4 Market Concentration Degree 32
5 VRE AND MRSA ANTIBIOTIC REGIONAL MARKET ANALYSIS 35
5.1 VRE and MRSA Antibiotic Sales by Regions (2016-2021) 35
5.1.1 Global VRE and MRSA Antibiotic Sales by Regions (2016-2021) 35
5.1.2 Global VRE and MRSA Antibiotic Revenue by Regions 36
5.2 VRE and MRSA Antibiotic Sales by Regions (2022-2027) 37
5.2.1 Global VRE and MRSA Antibiotic Sales by Regions (2022-2027) 37
5.2.2 Global VRE and MRSA Antibiotic Revenue by Regions 38
5.3 North America VRE and MRSA Antibiotic Market Analysis 39
5.3.1 North America VRE and MRSA Antibiotic Sales 39
5.3.2 Key Players in North America 39
5.4 Europe VRE and MRSA Antibiotic Market Analysis 40
5.4.1 Europe VRE and MRSA Antibiotic Sales 40
5.4.2 Key Players in Europe 40
5.5 China VRE and MRSA Antibiotic Market Analysis 41
5.5.1 China VRE and MRSA Antibiotic Sales 41
5.5.2 Key Players in China 41
5.6 Japan VRE and MRSA Antibiotic Market Analysis 42
5.6.1 Japan VRE and MRSA Antibiotic Sales 42
5.6.2 Key Players in Japan 42
5.7 South Korea VRE and MRSA Antibiotic Market Analysis 43
5.7.1 South Korea VRE and MRSA Antibiotic Sales 43
5.7.2 Key Players in South Korea 43
5.8 Latin America VRE and MRSA Antibiotic Market Analysis 44
5.8.1 Latin America VRE and MRSA Antibiotic Sales 44
5.8.2 Key Players in Latin America 44
6 VRE AND MRSA ANTIBIOTIC SEGMENT MARKET ANALYSIS (BY TYPE) 45
6.1 Global VRE and MRSA Antibiotic Market Size by Type (2016-2021) 45
6.1.1 Global VRE and MRSA Antibiotic Sales by Type (2016-2021) 45
6.1.2 Global VRE and MRSA Antibiotic Revenue by Type (2016-2021) 45
6.2 Global VRE and MRSA Antibiotic Market Size by Type (2022-2027) 46
6.2.1 Global VRE and MRSA Antibiotic Sales by Type (2022-2027) 46
6.2.2 Global VRE and MRSA Antibiotic Revenue by Type (2022-2027) 47
6.3 VRE and MRSA Antibiotic Price by Type 47
7 VRE AND MRSA ANTIBIOTIC SEGMENT MARKET ANALYSIS (BY APPLICATION) 49
7.1 Global VRE and MRSA Antibiotic Sales Market Share by Application (2016-2021) 49
7.2 Global VRE and MRSA Antibiotic Sales Market Share by Application (2022-2027) 49
8 KEY COMPANIES PROFILED 51
8.1 Pfizer 51
8.1.1 Pfizer Corporation Information 51
8.1.2 Pfizer Description and Business Overview 51
8.1.3 Pfizer VRE and MRSA Antibiotic Sales, Revenue and Gross Margin (2018-2021) 52
8.1.4 Pfizer VRE and MRSA Antibiotic Product Portfolio 52
8.1.5 Pfizer Recent Developments/Updates 54
8.2 Lilly 54
8.2.1 Lilly Corporation Information 54
8.2.2 Lilly Description and Business Overview 55
8.2.3 Lilly VRE and MRSA Antibiotic Sales, Revenue and Gross Margin (2018-2021) 55
8.2.4 Lilly VRE and MRSA Antibiotic Product Portfolio 56
8.2.5 Lilly Recent Developments/Updates 57
8.3 Sanofi Aventis 57
8.3.1 Sanofi Aventis Corporation Information 57
8.3.2 Sanofi Aventis Description and Business Overview 57
8.3.3 Sanofi Aventis VRE and MRSA Antibiotic Sales, Revenue and Gross Margin (2018-2021) 58
8.3.4 Sanofi Aventis VRE and MRSA Antibiotic Product Portfolio 58
8.3.5 Sanofi Aventis Recent Developments/Updates 59
8.4 Merck 60
8.4.1 Merck Corporation Information 60
8.4.2 Merck Description and Business Overview 60
8.4.3 Merck VRE and MRSA Antibiotic Sales, Revenue and Gross Margin (2018-2021) 61
8.4.4 Merck VRE and MRSA Antibiotic Product Portfolio 61
8.4.5 Merck Recent Developments/Updates 62
8.5 Fresenius Kabi 62
8.5.1 Fresenius Kabi Corporation Information 62
8.5.2 Fresenius Kabi Description and Business Overview 62
8.5.3 Fresenius Kabi VRE and MRSA Antibiotic Sales, Revenue and Gross Margin (2018-2021) 63
8.5.4 Fresenius Kabi VRE and MRSA Antibiotic Product Portfolio 63
8.5.5 Fresenius Kabi Recent Developments/Updates 64
8.6 Xellia Pharmaceuticals (Novo Holdings) 65
8.6.1 Xellia Pharmaceuticals (Novo Holdings) Corporation Information 65
8.6.2 Xellia Pharmaceuticals (Novo Holdings) Description and Business Overview 65
8.6.3 Xellia Pharmaceuticals (Novo Holdings) VRE and MRSA Antibiotic Sales, Revenue and Gross Margin (2018-2021) 66
8.6.4 Xellia Pharmaceuticals (Novo Holdings) VRE and MRSA Antibiotic Product Portfolio 66
8.6.5 Xellia Pharmaceuticals (Novo Holdings) Recent Developments/Updates 67
8.7 Zhejiang Medicine 68
8.7.1 Zhejiang Medicine Corporation Information 68
8.7.2 Zhejiang Medicine Description and Business Overview 68
8.7.3 Zhejiang Medicine VRE and MRSA Antibiotic Sales, Revenue and Gross Margin (2018-2021) 69
8.7.4 Zhejiang Medicine VRE and MRSA Antibiotic Product Portfolio 70
8.8 Zhejiang Hisun Pharmaceutical 70
8.8.1 Zhejiang Hisun Pharmaceutical Corporation Information 70
8.8.2 Zhejiang Hisun Pharmaceutical Description and Business Overview 71
8.8.3 Zhejiang Hisun Pharmaceutical VRE and MRSA Antibiotic Sales, Revenue and Gross Margin (2018-2021) 71
8.8.4 Zhejiang Hisun Pharmaceutical VRE and MRSA Antibiotic Product Portfolio 72
8.8.5 Zhejiang Hisun Pharmaceutical Recent Developments/Updates 72
8.9 North China Pharmaceutical 72
8.9.1 North China Pharmaceutical Corporation Information 72
8.9.2 North China Pharmaceutical Description and Business Overview 73
8.9.3 North China Pharmaceutical VRE and MRSA Antibiotic Sales, Revenue and Gross Margin (2018-2021) 73
8.9.4 North China Pharmaceutical VRE and MRSA Antibiotic Product Portfolio 74
8.10 Korea United Pharm 75
8.10.1 Korea United Pharm Corporation Information 75
8.10.2 Korea United Pharm Description and Business Overview 75
8.10.3 Korea United Pharm VRE and MRSA Antibiotic Sales, Revenue and Gross Margin (2018-2021) 76
8.10.4 Korea United Pharm VRE and MRSA Antibiotic Product Portfolio 76
9 MARKETING CHANNEL, DISTRIBUTORS AND CUSTOMERS 77
9.1 VRE and MRSA Antibiotic Marketing Channel 77
9.1.1 Direct Channels 77
9.1.2 Indirect Channels 77
9.2 VRE and MRSA Antibiotic Distributors List 78
9.3 VRE and MRSA Antibiotic Customers 80
10 VRE AND MRSA ANTIBIOTIC MARKET DYNAMICS 81
10.1 VRE and MRSA Antibiotic Industry Trends 81
10.2 VRE and MRSA Antibiotic Growth Drivers 82
10.3 VRE and MRSA Antibiotic Market Challenges and Restraints 83
11 CONCLUSION 84
12 APPENDIX 85
12.1 Methodology/Research Approach 85
12.1.1 Research Programs/Design 85
12.1.2 Market Size Estimation 86
12.1.3 Market Breakdown and Data Triangulation 87
12.2 Data Source 88
12.2.1 Secondary Sources 88
12.2.2 Primary Sources 89
12.3 Author List 91
12.4 Disclaimer 91

　

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野の最新刊レポート

  • 本レポートと同分野の最新刊レポートはありません。

QYResearch社の
Fatal error: Uncaught TypeError: Cannot access offset of type string on string in /var/www/vhosts/dri.co.jp/httpdocs/PHPLibs/Smarty/templates_c/58b4bde6a9738f3389cd7dea7f4ef5c62fdc6c54_0.file.auto_report.tpl.php:630 Stack trace: #0 /var/www/vhosts/dri.co.jp/httpdocs/PHPLibs/Smarty/libs/sysplugins/smarty_template_resource_base.php(123): content_68d51da90169e8_18903235() #1 /var/www/vhosts/dri.co.jp/httpdocs/PHPLibs/Smarty/libs/sysplugins/smarty_template_compiled.php(114): Smarty_Template_Resource_Base->getRenderedTemplateCode() #2 /var/www/vhosts/dri.co.jp/httpdocs/PHPLibs/Smarty/libs/sysplugins/smarty_internal_template.php(216): Smarty_Template_Compiled->render() #3 /var/www/vhosts/dri.co.jp/httpdocs/PHPLibs/Smarty/libs/sysplugins/smarty_internal_template.php(385): Smarty_Internal_Template->render() #4 /var/www/vhosts/dri.co.jp/httpdocs/PHPLibs/Smarty/templates_c/f20300271f4eb0fb4a2cf788aaabb06be5646d19_0.file.frame-FULL.tpl.php(278): Smarty_Internal_Template->_subTemplateRender() #5 /var/www/vhosts/dri.co.jp/httpdocs/PHPLibs/Smarty/libs/sysplugins/smarty_template_resource_base.php(123): content_68b0f61a4d9868_07068969() #6 /var/www/vhosts/dri.co.jp/httpdocs/PHPLibs/Smarty/libs/sysplugins/smarty_template_compiled.php(114): Smarty_Template_Resource_Base->getRenderedTemplateCode() #7 /var/www/vhosts/dri.co.jp/httpdocs/PHPLibs/Smarty/libs/sysplugins/smarty_internal_template.php(216): Smarty_Template_Compiled->render() #8 /var/www/vhosts/dri.co.jp/httpdocs/PHPLibs/Smarty/libs/sysplugins/smarty_internal_templatebase.php(238): Smarty_Internal_Template->render() #9 /var/www/vhosts/dri.co.jp/httpdocs/PHPLibs/Smarty/libs/sysplugins/smarty_internal_templatebase.php(134): Smarty_Internal_TemplateBase->_execute() #10 /var/www/vhosts/dri.co.jp/httpdocs/auto/show_report.php(776): Smarty_Internal_TemplateBase->display() #11 {main} thrown in /var/www/vhosts/dri.co.jp/httpdocs/PHPLibs/Smarty/templates_c/58b4bde6a9738f3389cd7dea7f4ef5c62fdc6c54_0.file.auto_report.tpl.php on line 630